Browsing tag:


Patients with late-stage prostate cancer stand to benefit greatly since the approval of Enzalutamide, CAS number 915087-33-1. Sales of the brand name of Enzalutamide, Xtandi, have recently proven to garnish sizable profits for Medivation, the biopharmaceutical parent of this wonder drug. The launch of Enzalutamide in Europe and Asia in upcoming months are projected to[…]

Read More

As an antineoplastic drug used to treat cancer, docetaxel is also known by it’s brand name Taxotere. Docetaxel, CAS numbers 114977-28-5 and 148408-66-6, is primarily used to treat ovarian, breast, and non-small cell lung cancer. Also classified as a plant alkaloid medication, docetaxel is related to Taxol, which is a rare Pacific yew tree Taxus[…]

Read More

A recent study conducted by the Queens University Belfasts School of Pharmacy revealed the ability of the recombinant protein FKBPL to inhibit tumor growth by disrupting the blood supply to these tumors. This method of cancer treatment called neovascularization is certainly not new with several agents exhibiting the same mode of action already available in[…]

Read More

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service